Compare Heron Therapeutics Inc (HRTX) vs uniQure N.V. Ordinary Shares (QURE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs uniQure N.V. Ordinary Shares — how do they compare? Heron Therapeutics Inc trades at $0.37 (market cap $74.18M), while uniQure N.V. Ordinary Shares trades at $20.78 (market cap $1.48B). The key difference: uniQure N.V. Ordinary Shares is far larger — about 20× Heron Therapeutics Inc's market cap, and uniQure N.V. Ordinary Shares is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 36 Days and uniQure N.V. Ordinary Shares for 0 Days on average.
| HRTX | QURE | |
|---|---|---|
Market Cap | $74.18M | $1.48B |
Volume | 1,857,401 | 2,488,780 |
Sector | Health | Health |
52-Week High | $1.49 | $70.59 |
52-Week Low | $0.27 | $9.03 |
Typical Hold Time | 36 Days | 0 Days |
Enterprise Value | $180.92M | $728.62M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.3906, down 6.02% today, with a bullish technical signal from moving averages and oscillators. The company reported Q2 2026 revenue of $37.7 million but missed EPS estimates. Despite a high gross margin of 70.07%, it posted a net loss of -$20.20 million in 2025. Analyst consensus is strongly positive with 17 buy ratings. Recent news highlights earnings results and competitive comparisons.
The outlook remains speculative given persistent losses and negative ROE, but strong analyst support and improving cash flow trends offer potential upside. Key risks include profitability challenges and revenue volatility. Investors should weigh the bullish sentiment against fundamental weaknesses.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About uniQure N.V. Ordinary Shares
uniQure N.V. is a biotechnology company that develops gene therapies for rare and severe genetic diseases, marketing HEMGENIX for hemophilia B and advancing its AAV-based miQURE platform in programs such as AMT-130 for Huntington's disease.
Read more on QURE →
